Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1479-5876
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target ; volume:19 ; number:1 ; day:26 ; month:9 ; year:2021 ; pages:1-18 ; date:12.2021
Journal of translational medicine ; 19, Heft 1 (26.9.2021), 1-18, 12.2021
- Urheber
-
Capone, Emily
Iacobelli, Stefano
Sala, Gianluca
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12967-021-03085-w
- URN
-
urn:nbn:de:101:1-2021121621505302325777
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:25 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Capone, Emily
- Iacobelli, Stefano
- Sala, Gianluca
- SpringerLink (Online service)
Ähnliche Objekte (12)
Role of galectin-3 in melanoma progression
Role of galectin-3 in melanoma progression
B4GALT1-dependent galectin-8 binding with TGF-β receptor suppresses colorectal cancer progression and metastasis
Regulation of Tumor Progression by Extracellular Galectin-3
Selection of Galectin‐Binding Ligands from Synthetic Glycopeptide Libraries
Galectin Binding to Neo-Glycoproteins: LacDiNAc Conjugated BSA as Ligand for Human Galectin-3
A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target
Galectin-3: an immune checkpoint target for musculoskeletal tumor patients
Proteogenomic Landscape of Breast Ductal Carcinoma Reveals Tumor Progression Characteristics and Therapeutic Targets
Characterisation of mRNA binding proteins as potential therapeutic targets : models and tools
Galectin-1 promotes hepatocellular carcinoma and the combined therapeutic effect of OTX008 galectin-1 inhibitor and sorafenib in tumor cells
Evaluation of galectin-1 as a target for therapy in neuroblastoma
Role of galectin-3 in melanoma progression
Role of galectin-3 in melanoma progression
B4GALT1-dependent galectin-8 binding with TGF-β receptor suppresses colorectal cancer progression and metastasis
Regulation of Tumor Progression by Extracellular Galectin-3
Selection of Galectin‐Binding Ligands from Synthetic Glycopeptide Libraries
Galectin Binding to Neo-Glycoproteins: LacDiNAc Conjugated BSA as Ligand for Human Galectin-3
A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target
Galectin-3: an immune checkpoint target for musculoskeletal tumor patients
Proteogenomic Landscape of Breast Ductal Carcinoma Reveals Tumor Progression Characteristics and Therapeutic Targets
Characterisation of mRNA binding proteins as potential therapeutic targets : models and tools
Galectin-1 promotes hepatocellular carcinoma and the combined therapeutic effect of OTX008 galectin-1 inhibitor and sorafenib in tumor cells
Evaluation of galectin-1 as a target for therapy in neuroblastoma
Role of galectin-3 in melanoma progression
Role of galectin-3 in melanoma progression
B4GALT1-dependent galectin-8 binding with TGF-β receptor suppresses colorectal cancer progression and metastasis
Regulation of Tumor Progression by Extracellular Galectin-3
Selection of Galectin‐Binding Ligands from Synthetic Glycopeptide Libraries
Galectin Binding to Neo-Glycoproteins: LacDiNAc Conjugated BSA as Ligand for Human Galectin-3
A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target
Galectin-3: an immune checkpoint target for musculoskeletal tumor patients
Proteogenomic Landscape of Breast Ductal Carcinoma Reveals Tumor Progression Characteristics and Therapeutic Targets
Characterisation of mRNA binding proteins as potential therapeutic targets : models and tools
Galectin-1 promotes hepatocellular carcinoma and the combined therapeutic effect of OTX008 galectin-1 inhibitor and sorafenib in tumor cells